Search results
Results from the WOW.Com Content Network
On Oct. 10, Boston Scientific sent an urgent medical device advisory to all affected customers with recommendations. FDA classifies recall of Boston Scientific catheters as 'most serious' Skip to ...
Shares of the medical device maker rose 1.5% in afternoon trading. The approval makes the device, branded Agent, the first drug-coated balloon catheter in the U.S. to treat coronary in-stent ...
Boston Scientific Corporation (BSC), headquartered in Marlborough, Massachusetts and incorporated in Delaware, [2] is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular ...
An investigation showed that Boston's device, Obsidio Embolic, when used with a specific technique posed a higher risk of bowel ischemia during procedures to stop gastrointestinal (GI) bleeding ...
Boston Scientific's Lotus Valve system was awarded CE approval in October 2013. It allows the final position to be assessed and evaluated before release and has been designed to minimise regurgitation. [12] Boston Scientific has since retired the device as of January 11, 2021. [13]
A drug-eluting stent (DES) is a small mesh tube that is placed in the arteries to keep them open in the treatment of vascular disease.The stent slowly releases a drug to block cell proliferation (a biological process of cell growth and division), thus preventing the arterial narrowing that can occur after stent implantation.
Covered stents carry the advantage of preventing tumours from growing into the stent, although they run the risk of increased migration after deployment. [6] A plastic self-expanding stent (Polyflex, Boston Scientific) has also been developed for similar applications. It confers an additional advantage as it is designed to be removable, and may ...
Medical-device maker Boston Scientific yesterday released data from a clinical trial showing that its Promus Element drug-eluting stent showed advantages over Abbott's Xience V drug-eluting stent ...